235 related articles for article (PubMed ID: 10338526)
1. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
Cleare W; Cherniak R; Casadevall A
Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
3. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.
Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1995 Sep; 63(9):3353-9. PubMed ID: 7642262
[TBL] [Abstract][Full Text] [Related]
4. Prevalence in Cryptococcus neoformans strains of a polysaccharide epitope which can elicit protective antibodies.
Cleare W; Mukherjee S; Spitzer ED; Casadevall A
Clin Diagn Lab Immunol; 1994 Nov; 1(6):737-40. PubMed ID: 8556529
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
Mukherjee J; Zuckier LS; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1994 Mar; 38(3):580-7. PubMed ID: 8203858
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.
Mukherjee J; Feldmesser M; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1995 Jul; 39(7):1398-405. PubMed ID: 7492075
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
Mukherjee S; Lee S; Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1994 Mar; 62(3):1079-88. PubMed ID: 8112842
[TBL] [Abstract][Full Text] [Related]
8. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans.
Feldmesser M; Kress Y; Casadevall A
J Infect Dis; 1998 Jun; 177(6):1639-46. PubMed ID: 9607844
[TBL] [Abstract][Full Text] [Related]
9. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection.
Feldmesser M; Casadevall A
J Immunol; 1997 Jan; 158(2):790-9. PubMed ID: 8992996
[TBL] [Abstract][Full Text] [Related]
10. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
[TBL] [Abstract][Full Text] [Related]
11. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.
Nussbaum G; Anandasabapathy S; Mukherjee J; Fan M; Casadevall A; Scharff MD
Infect Immun; 1999 Sep; 67(9):4469-76. PubMed ID: 10456888
[TBL] [Abstract][Full Text] [Related]
12. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
13. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
14. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Martinez LR; Moussai D; Casadevall A
Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.
Brandt S; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925
[TBL] [Abstract][Full Text] [Related]
16. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.
Casadevall A; DeShaw M; Fan M; Dromer F; Kozel TR; Pirofski LA
Infect Immun; 1994 Sep; 62(9):3864-72. PubMed ID: 8063403
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy.
Goldman DL; Casadevall A; Zuckier LS
J Med Vet Mycol; 1997; 35(4):271-8. PubMed ID: 9292424
[TBL] [Abstract][Full Text] [Related]
18. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
[TBL] [Abstract][Full Text] [Related]
19. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide.
Valadon P; Nussbaum G; Oh J; Scharff MD
J Immunol; 1998 Aug; 161(4):1829-36. PubMed ID: 9712050
[TBL] [Abstract][Full Text] [Related]
20. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
Netski D; Kozel TR
Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]